


Annual Report 2018

Cochrane Kidney and Transplant



Contents

1	Highlights for 2018	4
1.1	Review publication	4
1.2	Review contributors	4
1.3	Trials register	4
1.4	Promotional resources and training	4
1.5	Impact factor	4
2	Personnel	5
2.1	Editorial staff	5
2.2	Editors	5
3	Publications and registered titles	6
3.1	New, updated, up-to-date and stable reviews	6
3.2	Published protocols	7
3.3	New registered titles	7
3.4	Titles registered 2004 to 2018	8
4	Editorial process	9
4.1	Protocols timeline	9
4.2	Reviews timeline	9
4.3	Time taken by referees	10
4.4	Mean time to publication	10
5	CKT Register of studies	11
6	Dissemination	12
6.1	Website	12
6.2	Twitter	12
6.3	Review promotion	12
6.4	“Cochrane Corner” - American Journal of Kidney Disease	12
6.5	Inclusion in guidelines 2017-2018	12
	<i>Kidney Disease – Improving Global Outcomes (KDIGO)</i>	12
	<i>National Institute for Health and Care Excellence (NICE)</i>	13
7	Partnership and collaboration	14

7.1	KDIGO guideline partnership	14
7.2	SONG core outcome sets	15
7.3	Cochrane Review Group Networks	15
8	Authors and referees	16
8.1	Contact authors	16
8.2	Authors	17
8.3	Referees	17
8.4	Author support	18
8.5	Training	18
9	Advisory Board	19
10	Funding and endorsements	19
10.1	Supporters	19
10.2	Partners	19
10.3	Endorsements	19
11	Cochrane Database of Systematic Reviews (CDSR): impact factor	20
11.1	CKT impact factor 2017	20
11.2	CKT impact factor compared with journals publishing in the same category	21
11.3	Wiley Online Library usage data	21
11.4	Alternative metrics	22



Australian Government
National Health and Medical Research Council



THE UNIVERSITY OF
SYDNEY

Based at:

BEAT CKD
BETTER EVIDENCE AND TRANSLATION IN CHRONIC KIDNEY DISEASE

ckr
CENTRE FOR
KIDNEY RESEARCH
The Children's Hospital
at Westmead

the
children's
hospital at Westmead

Endorsements: Asian-Pacific Society of Nephrology (APSN), Australian and New Zealand Society of Nephrology (ANZSN), International Pediatric Nephrology Association (IPNA), International Society of Nephrology (ISN), Kidney Health Australia (KHA), National Kidney Foundation (NKF)

1. Highlights for 2018

1.1 Review publication

- Total new reviews published by Cochrane Kidney and Transplant year ending 2018: **191**
- Publications in 2018:
 - Reviews published: **9**
 - Updates published: **4**
 - Reviews made stable: **1**
 - Protocols published: **9**
 - Titles registered: **7**

1.2 Review contributors

- Total active authors: **849**; 53 new authors added in 2018
- Total active referees: **748**; 31 new referees added in 2018

1.3 Trials register

- The CKT Register of Studies contains 25411 reports of 14022 studies

1.4 Promotional resources and training

- Website: <http://kidneyandtransplant.cochrane.org/>
- Twitter. We are active tweeters. Please follow us at @CochraneKidney
- Introduction to writing a Cochrane systematic review workshop was conducted in December 2018

1.5 Impact factor

- 2017 impact factor for the Cochrane Database of Systematic Reviews: **6.754** (up from the 2016 score of 6.264)
- 2017 Cochrane Kidney and Transplant impact factor: **4.750** (up from the 2016 score of 4.569)

2. Personnel

2.1 Editorial staff

Coordinating Editor

Professor Jonathan Craig

Deputy Coordinating Editors

Associate Professor Elaine Beller (*until June 2018*)

Professor Giovanni Strippoli

Managing Editor

Dr Fiona Russell

Copy Editor

Ms Narelle Willis

Information Specialist

Ms Gail Higgins

Administration Officer

Ms Leslee Edwards (*until Feb 2018*)

We are indebted to Dr Elisabeth Hodson for her support as part of the editorial base team.

2.2 Editors

Prof Arvind Bagga (India)

A/Prof Elaine Beller (Australia) (Statistical Editor)

NEW A/Prof Catherine Clase (Canada) (*from September 2018*)

Dr Emmanuel Effa (Nigeria)

Dr Elisabeth Hodson (Australia)

Prof Vivekanand Jha (India)

Prof David Johnson (Australia)

Prof Petra Macaskill (Australia) (DTA Editor)

A/Prof Suetonia Palmer (New Zealand)

NEW Prof Pietro Ravani (Canada) (*from August 2018*)


Dr Matthew Roberts (Australia)

A/Prof Armando Teixeira-Pinto (Australia) (Statistical Editor)

Prof Angela Webster (Australia)

Mr Colin Wilson (UK)

3. Publications and registered titles



Summary of reviews, protocols and updated/up-to-date reviews published in *The Cochrane Database of Systematic Reviews* (issues 1 to 12, 2018).

3.1 New, updated, up-to-date¹ and stable² reviews

- 1. Antibiotics for asymptomatic bacteriuria in kidney transplant recipients (new)**
Included studies: 2 (212 participants)
- 2. Antimicrobial lock solutions for preventing catheter-related infections in haemodialysis (new)**
Included studies: 39 (4216 participants)
- 3. Biocompatible dialysis fluids for peritoneal dialysis (update)**
Included studies in original review: 36 (2719 participants)
Included studies in this update: 42 (3262 participants)
- 4. Early versus late ureteric stent removal after kidney transplantation (new)**
Included studies: 5 (1127 participants)
- 5. Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function (made stable – replaced by 6)**
Included studies: 23 (1459 participants)
- 6. Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function (new)**
Included studies 26 (8835 participants)
- 7. Immunosuppressive treatment for proliferative lupus nephritis (update)**
Included studies in original review: 25 (915 participants)
Included studies in this update: 67 (4791 participants)

¹ New search performed, no new studies identified

² No new or ongoing studies identified in last 5 years; no longer being updated

8. **Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease (new)**
Included studies: 44 (13,036 participants)
9. **Interventions for chronic non-hypovolaemic hypotonic hyponatraemia (new)**
Included studies: 35 (3429 participants)
10. **Low protein diets for non-diabetic adults with chronic kidney disease (update)**
Included studies in original review: 7 (1494 participants)
Included studies in this update: 17 (2996 participants)
11. **Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease (new)**
Included studies: 5 (833 participants)
12. **Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD) (update)**
Included studies in original review: 60 (7631 participants)
Included studies in this update: 104 (13,744 participants)
13. **Timing of renal replacement therapy initiation for acute kidney injury (new)**
Included studies: 5 (1084 participants)
14. **Treatment for hepatitis C virus-associated mixed cryoglobulinaemia (new)**
Included studies: 10 (394 participants)

3.2 Published protocols


1. Aldosterone antagonists for people with chronic kidney disease requiring dialysis
2. Interventions for antibody-mediated acute rejection in kidney transplant recipients
3. Interventions for fatigue in people with chronic kidney disease requiring dialysis
4. Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome
5. Interventions for weight loss in people with chronic kidney disease who are overweight or obese
6. Perioperative antibiotics for preventing post-surgical site infections in solid organ transplant patients
7. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease
8. Pre-emptive versus non pre-emptive kidney transplantation for end-stage kidney disease
9. Urgent-start peritoneal dialysis versus conventional-start peritoneal dialysis for people with chronic kidney disease

3.3 New registered titles

1. Carnitine supplements for people with chronic kidney disease requiring dialysis
2. Interventions for BK virus infection in kidney transplant recipients
3. Interventions for osteoporosis in people with chronic kidney disease stages 2-5D
4. Less intensive versus conventional haemodialysis for people with end-stage kidney disease

5. Metformin for preventing the progression of chronic kidney disease
6. Perioperative antibiotics for preventing post-surgical site infections in solid organ transplant recipients
7. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease


3.4 Titles registered 2004 to 2018



4. Editorial process


4.1 Protocols timeline

Median time taken (weeks) from title registration until protocol submitted for publication (sorted by year draft submitted for refereeing).




4.2 Reviews timeline

Median time taken (weeks) from protocol submitted for publication until review submitted for publication (sorted by year draft review submitted for refereeing).



4.3 Time taken by referees


Mean time taken (weeks \pm 95% CI) to referee a protocol, review or update from sending documents to referee until comments received—sorted by year draft submitted for peer review.



4.4 Mean time to publication

Time (months, mean and 95% CI) taken from:


- Title registration to protocol inclusion in The Cochrane Database of Systematic Reviews (CDSR)
- Time from protocol inclusion until review inclusion in CDSR
- Time from title registration until review inclusion in CDSR




5. CKT Register of studies

Cochrane Kidney and Transplant develop and maintain a Register of Studies. It is a database of randomised controlled trials in kidney disease populated from a variety of sources that reflects the scope of our Group. As of January 2019, the Register contained 25411 reports of 14022 studies.

Source of records in CKT Specialised Register



As of January 2019, 27% (n=3737) of the studies in the CKT Register of Studies (n=14022) are Included Studies in CKT systematic reviews. Another 18% (n=2490) of studies are Awaiting Classification in CKT systematic reviews currently in production.



6. Dissemination

Cochrane Kidney and Transplant continues to maintain and develop communication with our partners and stakeholders.

6.1 Website

Our website is located at <http://kidneyandtransplant.cochrane.org/> where you can find:

- Information on our scope, our team and our supporters and sponsors
- Links to our newsletters, annual reports and brochures.
- All our reviews, protocols and registered titles
- Resources for authors and referees on writing a review
- Online membership form, workshop details
- Ongoing trials in Nephrology (with links to Clinicaltrials.gov)

6.2 Twitter

- Twitter: @CochraneKidney. We Tweet regularly, promoting newly published Cochrane Kidney and Transplant reviews and news of interest. We added 343 new followers in 2018, to end the year with a total of 1829 followers.

6.3 Review promotion

- Each new review and update is promoted using a “blogshot” (summary graphic) via twitter and on the homepage of our website.

6.4 “Cochrane Corner” - American Journal of Kidney Disease

In 2018 CKT and the *American Journal of Kidney Disease (AJKD)* agreed to collaborate to publish a regular summary and accompanying commentary of a recently published Cochrane Review in *AJKD* called Cochrane Corner. This replaces the Cochrane Commentaries previously published in *Nephrology*.

The first Cochrane Corner was published in November 2018:

- [Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review](#)
- [Commentary - An Update on Therapies for Proliferative Lupus Nephritis: How Certain Can We Be About the Evidence?](#)

6.5 Inclusion in guidelines 2017-2018

Kidney Disease – Improving Global Outcomes (KDIGO)

KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) (KI – sup Vol 7 issue 1 July 2017)

- Liu Z, Su G, Guo X, et al. Dietary interventions for mineral and bone disorder in people with chronic kidney disease. *Cochrane Database Syst Rev.* 2015:CD010350
- Hahn D, Hodson EM, Craig JC. Interventions for metabolic bone disease in children with chronic kidney disease. *Cochrane Database Syst Rev.* 2015: CD008327.

KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease (KI-Sup Vol 8 issue 3 2018)

- Bravo Zuniga JI, Loza Munarriz C, Lopez-Alcalde J. Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units. *Cochrane Database Syst Rev.* 2016:CD006420.
- Prabhu RA, Nair S, Pai G, et al. Interventions for dialysis patients with hepatitis C virus (HCV) infection. *Cochrane Database Syst Rev.* 2015: CD007003.

KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors (Transplantation Vol 101 *S 2017)

- Hodson EM, Ladhani M, Webster AC, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. *Cochrane Database Syst Rev.* 2013;2:CD003774.
- Wilson CH, Sanni A, Rix DA, et al. Laparoscopic versus open nephrectomy for live kidney donors. *Cochrane Database Syst Rev.* 2011:CD006124.
- Gupta A, Ahmed K, Kynaston HG, et al. Laparoendoscopic single-site donor nephrectomy (LESS-DN) versus standard laparoscopic donor nephrectomy. *Cochrane Database Syst Rev.* 2016:CD010850.

National Institute for Health and Care Excellence (NICE)

Renal replacement therapy and conservative management. NICE guideline NG107 Evidence review October 2018

1.3 RRT and conservative management. Modalities of RRT

- Nistor I, Palmer SC, Craig JC, Saglimbene V, Vecchio M, Covic A et al. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. *Cochrane Database of Systematic Reviews* 2015, Issue 5. Art. No.: CD006258. DOI: 10.1002/14651858.CD006258.pub2.
- Palmer SC, Palmer AR, Craig JC, Johnson DW, Stroumza P, Frantzen L et al. Home versus in-centre haemodialysis for end-stage kidney disease. *Cochrane Database of Systematic Reviews* 2014, Issue 11. Art. No.: CD009535. DOI: 10.1002/14651858.CD009535.pub2.
- Rabindranath KS, Adams J, Ali TZ, MacLeod AM, Vale L, Cody JD et al. Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease. *Cochrane Database of Systematic Reviews* 2007, Issue 2. Art. No.: CD006515. DOI: 10.1002/14651858.CD006515.
- Vale L, Cody JD, Wallace SA, Daly C, Campbell MK, Grant AM et al. Continuous ambulatory peritoneal dialysis (CAPD) versus hospital or home haemodialysis for end-stage renal disease in adults. *Cochrane Database of Systematic Reviews* 2004, Issue 4. Art. No.: CD003963. DOI: 10.1002/14651858.CD003963.pub2.
- Zhu B, Jun M, Jardine MJ, Wang YJ, Perkovic V. Haemodialysis duration, frequency and intensity for end-stage kidney disease. *Cochrane Database of Systematic Reviews* 2012, Issue 9. Art. No.: CD010064. DOI: 10.1002/14651858.CD010064.

1.7 RRT and conservative management Evidence review for dietary management and fluid restriction

- Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD001892. DOI: 10.1002/14651858.CD001892.pub3.
- Fry KM, Chan M. Long-term nutritional interventions for adult kidney transplant recipients. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD006862. DOI: dx.doi.org/10.1002/14651858.CD006862.
- McMahon EJ, Campbell KL, Bauer JD, Mudge DW. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No.: CD010070. DOI: 10.1002/14651858.CD010070.pub2

7. Partnership and collaboration

7.1 KDIGO guideline partnership

On January 9, 2018 Cochrane Kidney Transplant (CKT) entered into an agreement with Kidney Disease: Improving Global Outcomes (KDIGO) to undertake the evidence review for two clinical practice guideline updates (Glomerulonephritis and Management of blood pressure in CKD) and one de novo clinical practice guideline (Management of diabetes and CKD).

The CKT-KDIGO partnership represents a new approach to guideline development by using high-quality Cochrane Reviews to provide the foundation for the guideline evidence review. In addition, the project is utilising the innovative online guideline publishing platform MAGICapp, which allows for a more transparent link between evidence and recommendation and makes updating clinical practice guidelines more efficient.

Twenty-seven existing CKT Reviews formed the basis of the evidence review for the guidelines and were updated with searches in 2018. Additionally, non-Cochrane reviews were undertaken as required.

CKT met with KDIGO to finalise the scope of the guidelines in February 2018 (Glomerulonephritis and Blood pressure in CKD guidelines) and April 2018 (Diabetes in CKD guideline). In August 2018 CKT met with the Glomerulonephritis guideline workgroup to present and discuss the evidence review, and in January 2019 CKT met with the blood pressure workgroup and diabetes workgroup to present and discuss the evidence reviews. CKT is currently finalising the guideline evidence after the feedback received from the workgroups and working towards publishing the Cochrane Review updates that formed the basis of these guidelines.



7.2 SONG core outcome sets

In September, 2017, Cochrane Kidney and Transplant decided to incorporate core outcome sets in chronic kidney disease developed by the Standardised Outcomes in Nephrology Initiative (SONG) as they became available. CKT now requires that all available SONG core outcome sets are included in our reviews if those outcome sets are relevant to the included participants. They can be primary or secondary outcomes and additional outcomes can also be included. The core outcomes are included due to their relevance for consumers (e.g. decision-makers, patients) even if they do not appear to be directly relevant to the intervention.

In 2018, core outcome sets for haemodialysis and transplant (SONG-HD: Fatigue; Cardiovascular disease; Vascular access; Mortality and SONG-Tx: Graft health; Cardiovascular disease; Cancer; Infection; Life participation; Mortality) were available. These were incorporated into our Review Proposal Form and protocol template documentation and included in all relevant new titles and unpublished protocols.



7.3 Cochrane Review Group Networks


Starting in 2018, Cochrane has created eight new Networks of Cochrane Review Groups to support and help coordinate work across multiple Review Groups dealing with similar topics. Each Network has a Senior Editor, Associate Editor and Network Fellow. CKT belongs to the “Abdomen and Endocrine Network” (previously called Long-term Conditions and Ageing).



8. Authors and referees

Although based in Australia, Cochrane Kidney and Transplant is an international group that seeks to include authors and referees from around the world.


8.1 Contact authors



Contact authors

Africa (Kenya, Nigeria, South Africa); **Asia** (China, India, Japan, South Korea, Malaysia, Philippines, Taiwan, Thailand); **Central & South America** (Argentina, Brazil, Chile, Colombia, Peru, Uruguay), **Europe** (Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Poland, Romania, Russian Federation, Spain, Sweden, Switzerland, UK); **Middle East** (Israel, Palestine); **North America** (Canada, USA)


8.2 Authors



All authors (849)

Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia, Denmark, Ecuador, Egypt, France, Germany, Greece, India, Ireland, Israel, Italy, Japan, Kenya, Korea, South, Malaysia, Netherlands, New Zealand, Nigeria, Norway, Palestine, Peru, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, UK, USA, Uruguay, Venezuela

8.3 Referees



Referees (748)

Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Korea, South, Morocco, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Romania, Russian Federation, Singapore, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, UK, USA

8.4 Author support

In 2018, we regularly updated our existing resource documentation and templates in response to changes in Cochrane methodology and policy. We also created a number of new resources for authors to assist them in undertaking their review and maintaining Cochrane standards, including new Review Proposal Forms for diagnostic and prognostic reviews and an author guide to incorporating studies without full-text publications.

In addition, we continued to provide ongoing methodological, procedural and technical support via email to all our authors.

8.5 Training

In December, 2018 a 3-day workshop designed for authors of intervention reviews who wish to follow Cochrane methods was held at our editorial base in Sydney. The workshop was run in partnership with Cochrane Australia and we would like to thank the training coordinator, Matthew Page.

This three-day introductory workshop is designed for new authors starting a Cochrane systematic review and is a mixture of presentations and hands-on sessions which give an overview of all the methods required to write a protocol and get started on the review.

- Day 1 covers scoping the review, the process of writing a protocol and searching the literature for included studies.
- Day 2 covers assessing the risk of bias (critical appraisal) of included studies, and an introduction to meta-analysis, common data types encountered in systematic reviews, and using the Review Manager software package.
- Day 3 looks at analysis of more complex study designs and data types, exploring and interpreting results.

In addition, Cochrane Centres organise and run training workshops for authors in their region, see <http://www.cochrane.org/contact/centres>. Workshops and online training resources can be found at <http://training.cochrane.org/>, with a set of online modules that provide an introduction to systematic reviews at <http://training.cochrane.org/interactivelearning>.

9. Advisory Board

In April 2001 Cochrane Kidney and Transplant established an Advisory Board representing our major stakeholders that meets twice a year. The members of the Board in 2018 were:

- **Professor Gavin Becker** (Royal Melbourne Hospital)
- **Dr Michael Brydon** (Chief Executive, The Sydney Children's Hospitals Network)
- **Professor Jonathan Craig** (Cochrane Kidney and Transplant Co-ordinating Editor - ex officio)
- **Dr Magid Fahim** (Princess Alexandra Hospital)
- **Dr Celine Foote** (The George Institute for Global Health)
- **Professor Sally Green** (Co-Director Cochrane Australia)
- **Dr Elisabeth Hodson** (Department of Nephrology and the Centre for Kidney Research, The Children's Hospital at Westmead)
- **Dr Lisa Murphy** (Kidney Health Australia)
- **Dr Matthew Roberts (Chair)** (Eastern Health Clinical School, Monash University, ANZSN representative)
- **Dr Fiona Russell** (Cochrane Kidney and Transplant Managing Editor - ex officio)
- **Professor Giovanni Strippoli** (Cochrane Kidney and Transplant Deputy Co-ordinating Editor - ex officio)

10. Funding and endorsements

We are grateful for support from the following organisations:

10.1 Supporters

- National Health and Medical Research Council (NHMRC)
- BEAT-CKD Better Evidence and Translation in CKD
- Centre for Kidney Research
- The Children's Hospital at Westmead
- University of Sydney

10.2 Partners

- Kidney Disease: Improving Global Outcomes (KDIGO)

10.3 Endorsements

- Asian Pacific Society of Nephrology
- Australian & New Zealand Society of Nephrology (ANZSN)
- International Pediatric Nephrology Association (IPNA)
- International Society of Nephrology (ISN)
- Kidney Health Australia (KHA)
- National Kidney Foundation [US]

11. Cochrane Database of Systematic Reviews (CDSR): impact factor

11.1 CKT impact factor 2017

Released in November 2018, the 2017 Journal Impact Factor for the Cochrane Database of Systematic Reviews (CDSR) was **6.754**. This describes the ratio of the number of reviews published during 2015 and 2016 (1,764) to the number of citations these reviews received in 2017 (11,914).

The 2017 CRG Impact Factor for the Kidney and Transplant Group was **4.750** (44 publications cited 209 times). A review published by the Kidney and Transplant Group in 2015 or 2016 was cited, on average, 4.750 times in 2017.

The ten most cited reviews from the Kidney and Transplant Group contributing to the 2017 Impact Factor were:

CD Number	Title	Times Cited
CD010070.pub2	Altered dietary salt intake for people with chronic kidney disease	23
CD008772.pub2	Probiotics for preventing urinary tract infections in adults and children	16
CD001533.pub5	Corticosteroid therapy for nephrotic syndrome in children	14
CD010480.pub2	HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass	11
CD007013.pub2	Preoperative vascular access evaluation for haemodialysis patients	8
CD006258.pub2	Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease	7
CD003965.pub2	Immunosuppressive agents for treating IgA nephropathy	7
CD010294.pub2	Interventions for preventing the progression of autosomal dominant polycystic kidney disease	7
CD007746.pub2	Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients	7
CD009534.pub2	Antibiotics for asymptomatic bacteriuria	6

11.2 CKT impact factor compared with journals publishing in the same category

The CRG data was compared with journals in the relevant Journal Citation Reports subject categories. The journal with the top Impact Factor in the category is not always directly comparable – either because of the scope of the journal, or the number of reviews published.

CRG	Category (Median IF)	IF of journal ranked 10 th in the category	Highest ranked journal by IF
Kidney and Transplant Group	Urology & Nephrology	NEPHROLOGY DIALYSIS TRANSPLANTATION	EUROPEAN UROLOGY
4.750	2.038	4.602	17.581

11.3 Wiley Online Library usage data

The ten most accessed Reviews from Cochrane Kidney and Transplant in 2017 were:

CD Number	Review Title	Full text downloads
CD001321.pub5	Cranberries for preventing urinary tract infections	6,780
CD008772.pub2	Probiotics for preventing urinary tract infections in adults and children	4,454
CD011339	Diuretics for people with chronic kidney disease	2,885
CD009647.pub2	Clinical symptoms, signs and tests for identification of impending and current water-loss dehydration in older people	2,611
CD001533.pub5	Corticosteroid therapy for nephrotic syndrome in children	2,280
CD010070.pub2	Altered dietary salt intake for people with chronic kidney disease	2,194
CD010138.pub2	Loop diuretics for patients receiving blood transfusions	2,178
CD011998.pub2	Dietary interventions for adults with chronic kidney disease	1,988
CD005284.pub3	Treatment for peritoneal dialysis-associated peritonitis	1,773
CD010446.pub2	Chinese herbal medicine for treating recurrent urinary tract infections in women	1,731

11.4 Alternative metrics

Using the Altmetric system (<http://www.altmetric.com/>), further measures of the impact of Cochrane Reviews beyond cites and usage are able to be reported. Altmetric have created a cluster of servers that watch social media sites, newspapers, government policy documents and other sources for mentions of scholarly articles. The Altmetric Attention Score is a quantitative measure of the attention that a scholarly article has received.

Altmetric has tracked mentions of 9,179 articles from the CDSR up to August 2018.

The highest Altmetric Attention Scores from Cochrane Reviews published by the Kidney and Transplant Group in 2017 (scores retrieved 20th August 2018) were:

Score	Review Title	T	F	N	M
88	Glucose targets for preventing diabetic kidney disease and its progression	162	9	0	89
35	Dietary interventions for adults with chronic kidney disease	61	5	0	59
31	Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease	55	4	0	28
27	Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients	42	0	0	28
19	Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients	38	0	0	32
17	Probiotics for preventing urinary tract infection in people with neuropathic bladder	30	3	0	68
14	Peritoneal dialysis for acute kidney injury. - PubMed - NCBI	19	1	0	6
13	Interventions for treating central venous haemodialysis catheter malfunction	20	3	0	37
12	Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients	20	1	0	51
8	Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients	14	3	0	42

T=Twitterers F=Facebook walls N=News outlets M=Mendeley readers

Altmetric track 'mentions' from 17 different sources including references in policy documents, citations in Wikipedia pages and discussions on Peer Review sites. Only sources that contributed substantially to the scores of the Cochrane Reviews in the table above have been included.